Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 23, Number 2—February 2017

Multidrug-Resistant Candida haemulonii and C. auris, Tel Aviv, Israel

Ronen Ben-AmiComments to Author , Judith Berman, Ana Novikov, Edna Bash, Yael Shachor-Meyouhas, Shiri Zakin, Yasmin Maor, Jalal Tarabia, Vered Schechner, Amos Adler, and Talya Finn
Author affiliations: Tel Aviv University, Tel Aviv, Israel (R. Ben-Ami, J. Berman, S. Zakin, Y. Maor, V. Schechner, A. Adler); Tel Aviv Sourasky Medical Center, Tel Aviv (R. Ben-Ami, A. Novikov, E. Bash, J. Tarabia, V. Schechner, A. Adler, T. Finn); Ruth Rappaport Children's Hospital, Haifa, Israel (Y. Shachor-Meyouhas); Wolfson Medical Center, Holon, Israel (Y. Maor).

Main Article

Table 2

Comparison of colonized and noncolonized patients with Candida haemulonii, clinic A, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel*

p value Odds ratio (95% CI) Controls, n = 40 Cases, n = 20 Variable
0.015 NA 63.0 (43–94) 77.5 (44–91) Median age, y (range)
0.017 6.65 (1.26–65.0) 23 (57.5) 18 (90) Male sex
0.44 NA 48 (9–192) 40 (8–228) Median time in clinic A, mo (range)
0.022 NA 62.9 ± 3.61 47.7 ± 5.56 eGFR, mL/min/1.73m2, mean ± SEM
0.057 3.05 (0.88–11.2) 15 (37.5) 13 (65) Chronic kidney disease, stage 3–4
0.069 3.85 (0.76–21.0) 4 (10) 6 (30) Dialysis
0.003 5.5 (1.51–21.1) 10 (25) 13 (65) Ischemic heart disease
0.27 2.05 (0.59–7.37) 19 (47.5) 13 (65) Diabetes mellitus
1.00 0.80 (0.13–5.84) 35 (87.5) 17 (85) Peripheral vascular disease

*Values are no. (%) patients except as indicated. eGFR, glomerular filtration rate, estimated using the Modification of Diet in Renal Disease (MDRD) equation (22); NA, odds ratio is not applicable for continuous variables.

Main Article

  1. Magill  SS, Edwards  JR, Bamberg  W, Beldavs  ZG, Dumyati  G, Kainer  MA, et al.; Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370:1198208. DOIPubMedGoogle Scholar
  2. Kullberg  BJ, Arendrup  MC. Invasive Candidiasis. N Engl J Med. 2015;373:144556. DOIPubMedGoogle Scholar
  3. Garey  KW, Rege  M, Pai  MP, Mingo  DE, Suda  KJ, Turpin  RS, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006;43:2531. DOIPubMedGoogle Scholar
  4. Andes  DR, Safdar  N, Baddley  JW, Playford  G, Reboli  AC, Rex  JH, et al.; Mycoses Study Group. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis. 2012;54:111022. DOIPubMedGoogle Scholar
  5. Alexander  BD, Johnson  MD, Pfeiffer  CD, Jiménez-Ortigosa  C, Catania  J, Booker  R, et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis. 2013;56:172432. DOIPubMedGoogle Scholar
  6. Satoh  K, Makimura  K, Hasumi  Y, Nishiyama  Y, Uchida  K, Yamaguchi  H. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009;53:414. DOIPubMedGoogle Scholar
  7. Lee  WG, Shin  JH, Uh  Y, Kang  MG, Kim  SH, Park  KH, et al. First three reported cases of nosocomial fungemia caused by Candida auris. J Clin Microbiol. 2011;49:313942. DOIPubMedGoogle Scholar
  8. Chowdhary  A, Sharma  C, Duggal  S, Agarwal  K, Prakash  A, Singh  PK, et al. New clonal strain of Candida auris, Delhi, India. Emerg Infect Dis. 2013;19:16703. DOIPubMedGoogle Scholar
  9. Magobo  RE, Corcoran  C, Seetharam  S, Govender  NP. Candida auris-associated candidemia, South Africa. Emerg Infect Dis. 2014;20:12501. DOIPubMedGoogle Scholar
  10. Chowdhary  A, Anil Kumar  V, Sharma  C, Prakash  A, Agarwal  K, Babu  R, et al. Multidrug-resistant endemic clonal strain of Candida auris in India. Eur J Clin Microbiol Infect Dis. 2014;33:91926. DOIPubMedGoogle Scholar
  11. Okinda  N, Kagotho  E, Castanheira  M, Njuguna  A, Omuse  G, Makau  P, et al. Candidemia at a referral hospital in sub-Saharan Africa: emergence of Candida auris as a major pathogen. European Conference on Clinical Microbiology and Infectious Diseases; 2014 May 10–13; Barcelona, Spain.
  12. Centers for Disease Control and Prevention. Global emergence of invasive infections caused by the multidrug-resistant yeast Candida auris [cited 2016 Jul 29].
  13. Public Health England. Candida auris identified in England [cited 2016 Jul 1].
  14. Schoch  CL, Seifert  KA, Huhndorf  S, Robert  V, Spouge  JL, Levesque  CA, et al.; Fungal Barcoding Consortium; Fungal Barcoding Consortium Author List. Nuclear ribosomal internal transcribed spacer (ITS) region as a universal DNA barcode marker for Fungi. Proc Natl Acad Sci U S A. 2012;109:62416. DOIPubMedGoogle Scholar
  15. Edgar  RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 2004;32:17927. DOIPubMedGoogle Scholar
  16. Saitou  N, Nei  M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol. 1987;4:40625.PubMedGoogle Scholar
  17. Kimura  M. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol. 1980;16:11120. DOIPubMedGoogle Scholar
  18. Kumar  S, Stecher  G, Tamura  K. MEGA7: Molecular Evolutionary Genetics Analysis version 7.0 for bigger datasets. Mol Biol Evol. 2016;33:18704. DOIPubMedGoogle Scholar
  19. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A3. Wayne (PA): The Institute; 2008.
  20. Maesaki  S, Marichal  P, Vanden Bossche  H, Sanglard  D, Kohno  S. Rhodamine 6G efflux for the detection of CDR1-overexpressing azole-resistant Candida albicans strains. J Antimicrob Chemother. 1999;44:2731. DOIPubMedGoogle Scholar
  21. Kolaczkowski  M, van der Rest  M, Cybularz-Kolaczkowska  A, Soumillion  JP, Konings  WN, Goffeau  A. Anticancer drugs, ionophoric peptides, and steroids as substrates of the yeast multidrug transporter Pdr5p. J Biol Chem. 1996;271:315438. DOIPubMedGoogle Scholar
  22. Levey  AS, Coresh  J, Greene  T, Stevens  LA, Zhang  YL, Hendriksen  S, et al.; Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:24754. DOIPubMedGoogle Scholar
  23. Pfaller  MA, Espinel-Ingroff  A, Canton  E, Castanheira  M, Cuenca-Estrella  M, Diekema  DJ, et al. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution. J Clin Microbiol. 2012;50:20406. DOIPubMedGoogle Scholar
  24. Park  BJ, Arthington-Skaggs  BA, Hajjeh  RA, Iqbal  N, Ciblak  MA, Lee-Yang  W, et al. Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome. Antimicrob Agents Chemother. 2006;50:128792. DOIPubMedGoogle Scholar
  25. Chatterjee  S, Alampalli  SV, Nageshan  RK, Chettiar  ST, Joshi  S, Tatu  US. Draft genome of a commonly misdiagnosed multidrug resistant pathogen Candida auris. BMC Genomics. 2015;16:686. DOIPubMedGoogle Scholar
  26. Public Health England. Guidance for the laboratory investigation, management and infection prevention and control for cases of Candida auris [cited 2016 Jul 1].
  27. de Almeida  JN Jr, Assy  JG, Levin  AS, Del Negro  GM, Giudice  MC, Tringoni  MP, et al. Candida haemulonii complex species, Brazil, January 2010–March 2015. Emerg Infect Dis. 2016;22:5613. DOIPubMedGoogle Scholar
  28. Kumar  A, Prakash  A, Singh  A, Kumar  H, Hagen  F, Meis  JF, et al. Candida haemulonii species complex: an emerging species in India and its genetic diversity assessed with multilocus sequence and amplified fragment-length polymorphism analyses. Emerg Microbes Infect. 2016;5:e49. DOIPubMedGoogle Scholar
  29. Kim  MN, Shin  JH, Sung  H, Lee  K, Kim  EC, Ryoo  N, et al. Candida haemulonii and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features. Clin Infect Dis. 2009;48:e5761. DOIPubMedGoogle Scholar
  30. Ramos  LS, Figueiredo-Carvalho  MH, Barbedo  LS, Ziccardi  M, Chaves  AL, Zancopé-Oliveira  RM, et al. Candida haemulonii complex: species identification and antifungal susceptibility profiles of clinical isolates from Brazil. J Antimicrob Chemother. 2015;70:1115. DOIPubMedGoogle Scholar
  31. Ruan  SY, Kuo  YW, Huang  CT, Hsiue  HC, Hsueh  PR. Infections due to Candida haemulonii: species identification, antifungal susceptibility and outcomes. Int J Antimicrob Agents. 2010;35:858. DOIPubMedGoogle Scholar
  32. Khan  ZU, Al-Sweih  NA, Ahmad  S, Al-Kazemi  N, Khan  S, Joseph  L, et al. Outbreak of fungemia among neonates caused by Candida haemulonii resistant to amphotericin B, itraconazole, and fluconazole. J Clin Microbiol. 2007;45:20257. DOIPubMedGoogle Scholar
  33. Borman  AM, Szekely  A, Johnson  EM, Mitchell  AP. Comparative pathogenicity of United Kingdom isolates of the emerging pathogen Candida auris and other key pathogenic Candida species. mSphere. 2016;1.pii:e00189-16. PubMedGoogle Scholar

Main Article

Page created: January 12, 2017
Page updated: January 12, 2017
Page reviewed: January 12, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.